Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 24, Issue 1 , Pages 81-86, February 2010

Reproduction after breast cancer

  • Stefanos Zervoudis, MD, PhD (Gynaecologist and Breast Surgeon)

      Affiliations

    • University of Medicine and Pharmacy, C. Davila, Bucharest, Romania
    • Breast Department of Lito Hospital, Athens, Greece
    • MANOSMED: Mastology Association of the Northern and Southern Mediterranean-Mobile University of Mastology, Ioannina, Greece
    • These authors contributed equally to this article.
    • ,
  • George Iatrakis, MD, PhD (Gynaecologist-Obstetrician)

      Affiliations

    • MANOSMED: Mastology Association of the Northern and Southern Mediterranean-Mobile University of Mastology, Ioannina, Greece
    • Technological Educational Institution of Athens, Greece
    • Corresponding Author InformationCorresponding author.
    • These authors contributed equally to this article.
    • ,
  • Iordanis Navrozoglou, MD, PhD (Gynaecologist-Obstetrician)

      Affiliations

    • MANOSMED: Mastology Association of the Northern and Southern Mediterranean-Mobile University of Mastology, Ioannina, Greece
    • Department of Obstetrics & Gynaecology, University of Ioannina, Greece

published online 03 September 2009.

Breast cancer is the most frequently occurring cancer in women of developed countries, and as a result of new developments in breast cancer treatment, more women are cured after being diagnosed with this disease. It is important that fertility preservation strategies are addressed before chemotherapy, because chemotherapy may induce premature ovarian failure (depending on the woman's age, the drugs used, the dosage and duration of treatment). Among possible solutions are embryos or oocytes cryopreservation, ovarian tissue cryopreservation–freezing with a subsequent orthotopic and heterotopic autotransplantation, whole ovary cryopreservation, ovarian suppression with gonadotropin-releasing hormone (GnRH) analogues, which inhibit ovarian follicular depletion induced by chemotherapeutic agents and in vitro fertilisation (IVF) after ovulation induction with aromatase inhibitors or tamoxifen.

Keywords: breast cancer, chemotherapy, age, fertility preservation, reproduction

 

PII: S1521-6934(09)00111-4

doi:10.1016/j.bpobgyn.2009.08.008

Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 24, Issue 1 , Pages 81-86, February 2010

Article Tools